Navigation Links
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Date:6/24/2008

KENILWORTH, N.J., June 24 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 26, 2008, to shareholders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 1,621,414,244 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Aug. 15, 2008, to holders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 10,000,000 shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
2. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
3. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
4. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
5. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
6. Schering-Plough CEO Buys $2 Million in Common Shares
7. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
8. Schering-Plough Reports Financial Results for First Quarter of 2008
9. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
10. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
11. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
(Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
(Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... While radiation treatments deliver precise doses of high-energy ... to shrink tumors, oncologists have become increasingly concerned ... treatments to nerves responsible for upper body mobility. ... UC Davis Cancer Center researchers have taken the ...
... Department of Statistics and Centre for Complexity Science have ... the complex cell interactions that lead to cancer and ... such as Facebook for useful insights. An approach ... gain an understanding of a range of systems with ...
... As polar bears adapt to a warming Arctica frozen seascape ... unlikely source: snow goose eggs. New calculations show that changes ... nesting near the western Hudson Bay could provide at least ... new analysis appears in Polar Biology . "Over ...
Cached Biology News:UC Davis team refines cancer treatments to reduce potential nerve damage 2New tool could unpick complex cancer causes and help sociologists mine Facebook 2Goose eggs may help polar bears weather climate change 2
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: